Why I’d dump the NMC Health share price and buy this health stock instead

The NMC share price gained nearly 10% Thursday, but I think buying now could be courting disaster.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Shares in Smith & Nephew (LSE: SN) jumped 9.6% in early trading Thursday, on the back of strong revenue growth for 2019.

The company is big in orthopaedics, making hip and knee joints, and other related technology. In a world where wealth is rising, demand for high-tech healthcare is growing too.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

Revenue increased by 4.4% for the full year, and by 5.6% in the fourth quarter. That pushed group sales above $5bn for the first time in Smith & Nephew’s history.

The firm told us: “All global franchises and regions positively contributed to growth.” I think it’s telling that emerging markets saw a rise of 16.1%, and I’ll be looking there for further future gains.

Earnings per share dipped a little on a reported basis, from 76 cents a year ago to 68 cents. But on a trading basis, we saw a rise from 100.9 cents to 102.2 cents.


Cash generated from operations increased nicely, to $1,370m (from $1,108m), and the dividend is up 4% to 37.5 cents per share.

That’s a yield of only around 1.5%, but it’s very well covered by earnings. And right now I think it’s right for Smith & Nephew to prioritise investing for growth ahead of providing big dividend income. Smith & Nephew expects to see underlying revenue growth of between 3.5% and 4.5% in 2020, and that looks in line with analyst expectations.

Smith & Nephew shares are up 38% over the past 12 months, so are they getting a bit peaky now? Forecasts suggest a 2020 price-to-earnings ratio of 24, which might look a bit high. But if growth continues apace, I think that could still turn out to be good value.

It’s a growth company on a high growth valuation, but I think it’s fully deserved.

NMC chaos

The intrigue is growing at NMC Health (LSE: NMC), whose shares blipped up nearly 10% Thursday morning.

Under pressure since Muddy Waters released a scathing attack on the company’s governance and announced a short position, founder and co-chair Bavaguthu Raghuram Shetty resigned earlier this week. It all comes amid confusion over the size of Shetty’s shareholding, with nobody really seeming to know.

There’s an ongoing legal investigation into the mystery, and the firm gave us an update on 18 February. It wasn’t nice, saying: “The board remains disappointed in the disclosures made by Dr Shetty.” It adds that the board “continues to encourage Dr Shetty and his advisers to ascertain the correct legal position in relation to his ownership of Ordinary Shares without further delay.” 


The growing evidence seems bizarre. Shetty has apparently pledged a chunk of his shares against some bank loans. Other shareholders might own some of his reported holdings. And banks might have already sold some shares to enforce loan security. It boggles my mind.

Then on 19 February the story took a new twist. Czech investor Krupa Global Investments said it would not take a strategic stake in NMC unless Shetty is reinstated.

What should private investors do? I’m amazed that a FTSE 100 company can get into such an impenetrable mess. And if the board and chair can’t work out who owns what, how can we trust their competence in running the company’s finances?

I’ve admired NMC’s apparently successful growth in the past, but today I’d steer well clear.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Here’s a FTSE 250 stock to buy to benefit from the construction boom!

Jabran Khan details a FTSE 250 stock that could be primed to benefit from the infrastructure and construction boom.

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Is the Royal Mail share price a buying opportunity?

With a 6% dividend yield and a price-to-earnings ratio of 3, is the Royal Mail share price in buying territory?…

Read more »

Scene depicting the City of London, home of the FTSE 100
Investing Articles

3 FTSE 100 shares! Should I buy them?

I'm searching for the best FTSE 100 stocks to buy following recent market volatility. Are these blue-chip UK shares too…

Read more »

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Should I buy one of the cheapest shares on the FTSE 100 index?

This Fool explores one of the cheapest stocks on the FTSE 100 index by share price and decides if he…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

With trading suspended, where could the Eurasia Mining (LON:EUA) share price go next?

This morning, the EUA share price was suspended pending an announcement - so could improving sales send the share price…

Read more »

Hand holding pound notes
Investing Articles

Are the FTSE 100’s top income stocks a bargain?

The FTSE 100 is renowned for its value and dividend stocks. So, are the index's top income stocks worth a…

Read more »

Compass pointing towards 'best price'
Investing Articles

Scottish Mortgage shares have slumped 40%. Time to buy now?

Scottish Mortgage Investment Trust (LON: SMT) shares have rewarded shareholders well in recent years. I'm thinking of buying now they're…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

3 recession stocks I’d buy in a hurry

With the economic outlook getting worse, our writer highlights a trio of recession stocks he would consider buying for his…

Read more »